He must be talking about watermelon tic tacs.
We are further along than Merck on the trials. The only problem I see is that if Merck is allowed to submit positive data (if it is even positive) on very few patients, and Revive has to wait until 600 or 800. Let's acknowledge that people are more likely to sign up with Merck for the trials too. If that is the case, so be it, but our drug is so versatile and safe, that something great will still come of it as an anti-inflammatory for many health issues.
We have 8 trading days until the end of June. Let's see some magic from the 400 patients soon.
We wait.
News 
Market Data 
Discover 
